Last reviewed · How we verify

NCT06627335

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Recruiting now Last updated 11 December 2025
What this trial tests

trial testing Ruxolitinib Cream in Pregnancy Related in 5,621 participants. Currently enrolling.

Timeline
27 March 2023
Primary endpoint
15 August 2027
15 August 2028

Quick facts

Lead sponsorIncyte Corporation
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment5,621
Start date27 March 2023
Primary completion15 August 2027
Estimated completion15 August 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Incyte Corporation — full company profile →

Who can join

14 and older, female only, with Pregnancy Related or Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ruxolitinib Cream

Trials testing the same drug.

Other recruiting trials for Pregnancy Related

Currently open trials in the same condition.

Other Incyte Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06627335.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing